

IMMUNOTHERAPY WITH AUTOVACCINE IN CASES OF STOMACH CANCER

*O.V. Kirsenko, V.A. Cherniy, G.P. Potebnia,
G.S. Lisovenko, D.A. Rozumiy, O.A. Tanasienko*

Summary. Immediate and long-term results by using of antitumorous autovaccine (ATAV) in 86 cases of spreaded stomach cancer (SC) were analised, ATAV made by processing of autologic tumorous cells by cytotoxic lectins of *B. subtilis* B-7025. This results were compared with analogous indices of 74 patients, who recieve ATAV of first generation, produced from filtrate *B. subtilis* AB-56 cultural liquid (ATAV1). Immunotherapy with ATAV2 of patients with SC is safe and doesn't couse any complications, doesn't demand any concomitant treatment. Vaccination by ATAV2 have better tolerance in comparison with ATAV1. Combination of surgical treatment with prescription of ATAV2 in cases of resectable SC I–IV stage — increase general 5-years survival to 17% average. Efficacy of ATAV2 depend from clinical prognosis. Advantage of ATAV2 in combined treatment of patients with SC are shown.

Key words: *stomach cancer, antitumorous autovaccine, general survival.*